Intrexon (XON) Shares Up 6.3% After Insider Buying Activity

Intrexon Corp (NYSE:XON) shot up 6.3% on Wednesday after an insider bought additional shares in the company. The stock traded as high as $4.73 and last traded at $4.73. 2,716,579 shares traded hands during mid-day trading, an increase of 12% from the average session volume of 2,435,780 shares. The stock had previously closed at $4.45.

Specifically, major shareholder Randal J. Kirk sold 95,241 shares of the company’s stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $0.65, for a total value of $61,906.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Thomas D. Reed sold 225,500 shares of the company’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $4.18, for a total transaction of $942,590.00. Following the completion of the sale, the insider now directly owns 96,280 shares of the company’s stock, valued at $402,450.40. The disclosure for this sale can be found here. Insiders have sold 362,419 shares of company stock valued at $1,032,421 over the last three months. Insiders own 48.20% of the company’s stock.

A number of research firms recently weighed in on XON. Zacks Investment Research lowered shares of Intrexon from a “buy” rating to a “hold” rating in a research note on Monday, January 21st. Northland Securities reaffirmed a “hold” rating and issued a $7.00 price objective on shares of Intrexon in a research note on Tuesday. Finally, JMP Securities reaffirmed a “buy” rating and issued a $43.00 price objective on shares of Intrexon in a research note on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $28.60.

Intrexon (NYSE:XON) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.28) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.28). The business had revenue of $23.30 million during the quarter, compared to analysts’ expectations of $32.12 million. During the same period last year, the company earned ($0.36) earnings per share. The firm’s revenue was down 41.2% compared to the same quarter last year.

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its position in shares of Intrexon by 8.8% during the first quarter. Geode Capital Management LLC now owns 895,779 shares of the biotechnology company’s stock valued at $4,711,000 after buying an additional 72,631 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Intrexon by 4.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 411,662 shares of the biotechnology company’s stock valued at $2,166,000 after buying an additional 16,297 shares during the last quarter. GMT Capital Corp purchased a new stake in shares of Intrexon during the first quarter valued at about $3,548,000. The Manufacturers Life Insurance Company lifted its position in shares of Intrexon by 12.6% during the first quarter. The Manufacturers Life Insurance Company now owns 51,381 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 5,767 shares during the last quarter. Finally, First Eagle Investment Management LLC lifted its position in shares of Intrexon by 13.9% during the first quarter. First Eagle Investment Management LLC now owns 842,665 shares of the biotechnology company’s stock valued at $4,432,000 after buying an additional 102,934 shares during the last quarter. 84.92% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Intrexon (XON) Shares Up 6.3% After Insider Buying Activity” was posted by WKRB News and is owned by of WKRB News. If you are viewing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.wkrb13.com/2019/05/16/intrexon-xon-shares-up-6-3-after-insider-buying-activity.html.

Intrexon Company Profile (NYSE:XON)

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

Featured Article: Hedge Funds Explained

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.